Author: Mark A. Lemley
Publisher:
ISBN:
Category : Patent laws and legislation
Languages : en
Pages : 50
Book Description
In Re Cipro Cases I and II
Author: Mark A. Lemley
Publisher:
ISBN:
Category : Patent laws and legislation
Languages : en
Pages : 50
Book Description
Publisher:
ISBN:
Category : Patent laws and legislation
Languages : en
Pages : 50
Book Description
In Re Cipro Cases I and II
Author: Mark A. Lemley
Publisher:
ISBN:
Category : Antitrust law
Languages : en
Pages : 26
Book Description
Publisher:
ISBN:
Category : Antitrust law
Languages : en
Pages : 26
Book Description
In Re: Ciprofloxacin Hydrochloride Antitrust Litigation
Author:
Publisher:
ISBN:
Category : Antitrust law
Languages : en
Pages : 40
Book Description
The plaintiffs in In re: Ciprofloxacin hydrochloride (Cipro) Antitrust Litigation (consumers and advocacy groups), sued the the brand name antibiotic's manufacturer Bayer, and prospective manufacturers of cheaper generic version, claiming that the exclusion agreement under which proposed manufacturers agreed to defer entry into market until expiration of patent held by Bayer, in return for payments to be received from Bayer, was in violation of antitrust laws. This amicus brief supports the plaintiffs, arguing in part that the case should have been decided in federal circuit court and that exclusion payments are generally anticompetitive.
Publisher:
ISBN:
Category : Antitrust law
Languages : en
Pages : 40
Book Description
The plaintiffs in In re: Ciprofloxacin hydrochloride (Cipro) Antitrust Litigation (consumers and advocacy groups), sued the the brand name antibiotic's manufacturer Bayer, and prospective manufacturers of cheaper generic version, claiming that the exclusion agreement under which proposed manufacturers agreed to defer entry into market until expiration of patent held by Bayer, in return for payments to be received from Bayer, was in violation of antitrust laws. This amicus brief supports the plaintiffs, arguing in part that the case should have been decided in federal circuit court and that exclusion payments are generally anticompetitive.
The U.S. Court of Appeals for the First Circuit Concludes that a Reverse Payment Need Not Be in Cash (Loestrin).
Author: Michael A. Carrier
Publisher:
ISBN:
Category :
Languages : en
Pages : 5
Book Description
In the area of drug patent settlements, the First Circuit's ruling in In Re Loestrin 24 Antitrust Litigation is a crucial decision. Since the Supreme Court's ruling in FTC v. Actavis, much ink has been spilled on whether "payment" applies beyond cash. The vast majority of district courts (as well as the Third Circuit in the Lamictal case) have correctly found that it does. But the district court In re Loestrin did not. The issue is still alive, as the Supreme Court recently requested the plaintiffs' response to the defendants' petition for certiorari in Lamictal.In the Loestrin decision, the First Circuit held that non-cash conveyances present similar harms as cash transfers. It recognized that a contrary conclusion would lead to the evasion of Actavis and a promotion of form over substance.In this short article, I conclude that the Loestrin decision puts the nail in the coffin of the argument that Actavis is limited to cash. The Loestrin decision also effectively disposes of the possibility of Supreme Court review. There is no circuit split. The two federal appellate courts that have addressed the issue have clearly and unequivocally held that payment encompasses more than just cash. In dicta, the California Supreme Court in In re Cipro Cases I & II agreed. And all 9 district courts that have addressed the issue have held that payment encompasses non-cash conveyances.As the courts move on to confront issues left open by Actavis such as the appropriate antitrust framework, role of causation, and pleading requirements, the Loestrin decision should put the easy issue of whether payment is limited to cash firmly in the rearview mirror.
Publisher:
ISBN:
Category :
Languages : en
Pages : 5
Book Description
In the area of drug patent settlements, the First Circuit's ruling in In Re Loestrin 24 Antitrust Litigation is a crucial decision. Since the Supreme Court's ruling in FTC v. Actavis, much ink has been spilled on whether "payment" applies beyond cash. The vast majority of district courts (as well as the Third Circuit in the Lamictal case) have correctly found that it does. But the district court In re Loestrin did not. The issue is still alive, as the Supreme Court recently requested the plaintiffs' response to the defendants' petition for certiorari in Lamictal.In the Loestrin decision, the First Circuit held that non-cash conveyances present similar harms as cash transfers. It recognized that a contrary conclusion would lead to the evasion of Actavis and a promotion of form over substance.In this short article, I conclude that the Loestrin decision puts the nail in the coffin of the argument that Actavis is limited to cash. The Loestrin decision also effectively disposes of the possibility of Supreme Court review. There is no circuit split. The two federal appellate courts that have addressed the issue have clearly and unequivocally held that payment encompasses more than just cash. In dicta, the California Supreme Court in In re Cipro Cases I & II agreed. And all 9 district courts that have addressed the issue have held that payment encompasses non-cash conveyances.As the courts move on to confront issues left open by Actavis such as the appropriate antitrust framework, role of causation, and pleading requirements, the Loestrin decision should put the easy issue of whether payment is limited to cash firmly in the rearview mirror.
Drug-Induced Liver Injury
Author:
Publisher: Academic Press
ISBN: 0128173173
Category : Medical
Languages : en
Pages : 288
Book Description
Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. Includes the authority and expertise of leading contributors in pharmacology Presents the latest release in the Advances in Pharmacology series
Publisher: Academic Press
ISBN: 0128173173
Category : Medical
Languages : en
Pages : 288
Book Description
Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. Includes the authority and expertise of leading contributors in pharmacology Presents the latest release in the Advances in Pharmacology series
Indirect Purchaser Litigation Handbook
Author:
Publisher: American Bar Association
ISBN: 9781590318683
Category : Law
Languages : en
Pages : 428
Book Description
Publisher: American Bar Association
ISBN: 9781590318683
Category : Law
Languages : en
Pages : 428
Book Description
Reports of Cases Determined in the Courts of Appeal of the State of California
Author:
Publisher:
ISBN:
Category : Law reports, digests, etc
Languages : en
Pages : 1480
Book Description
Publisher:
ISBN:
Category : Law reports, digests, etc
Languages : en
Pages : 1480
Book Description
Generic drug entry prior to patent expiration an FTC study
Author:
Publisher: DIANE Publishing
ISBN: 1428951938
Category :
Languages : en
Pages : 129
Book Description
Publisher: DIANE Publishing
ISBN: 1428951938
Category :
Languages : en
Pages : 129
Book Description
Healthcare Antitrust, Settlements, and the Federal Trade Commission
Author: James Langenfeld
Publisher: Emerald Group Publishing
ISBN: 1787566005
Category : Business & Economics
Languages : en
Pages : 483
Book Description
This volume of Research in Law and Economics contains articles that address important legal and economic developments in the areas of healthcare, intellectual property and labor settlements, competitive effects, cartel overcharges, and the U.S. Federal Trade Commission (FTC)
Publisher: Emerald Group Publishing
ISBN: 1787566005
Category : Business & Economics
Languages : en
Pages : 483
Book Description
This volume of Research in Law and Economics contains articles that address important legal and economic developments in the areas of healthcare, intellectual property and labor settlements, competitive effects, cartel overcharges, and the U.S. Federal Trade Commission (FTC)
CDC Yellow Book 2018: Health Information for International Travel
Author: Centers for Disease Control and Prevention CDC
Publisher: Oxford University Press
ISBN: 0190628634
Category : Medical
Languages : en
Pages : 705
Book Description
THE ESSENTIAL WORK IN TRAVEL MEDICINE -- NOW COMPLETELY UPDATED FOR 2018 As unprecedented numbers of travelers cross international borders each day, the need for up-to-date, practical information about the health challenges posed by travel has never been greater. For both international travelers and the health professionals who care for them, the CDC Yellow Book 2018: Health Information for International Travel is the definitive guide to staying safe and healthy anywhere in the world. The fully revised and updated 2018 edition codifies the U.S. government's most current health guidelines and information for international travelers, including pretravel vaccine recommendations, destination-specific health advice, and easy-to-reference maps, tables, and charts. The 2018 Yellow Book also addresses the needs of specific types of travelers, with dedicated sections on: · Precautions for pregnant travelers, immunocompromised travelers, and travelers with disabilities · Special considerations for newly arrived adoptees, immigrants, and refugees · Practical tips for last-minute or resource-limited travelers · Advice for air crews, humanitarian workers, missionaries, and others who provide care and support overseas Authored by a team of the world's most esteemed travel medicine experts, the Yellow Book is an essential resource for travelers -- and the clinicians overseeing their care -- at home and abroad.
Publisher: Oxford University Press
ISBN: 0190628634
Category : Medical
Languages : en
Pages : 705
Book Description
THE ESSENTIAL WORK IN TRAVEL MEDICINE -- NOW COMPLETELY UPDATED FOR 2018 As unprecedented numbers of travelers cross international borders each day, the need for up-to-date, practical information about the health challenges posed by travel has never been greater. For both international travelers and the health professionals who care for them, the CDC Yellow Book 2018: Health Information for International Travel is the definitive guide to staying safe and healthy anywhere in the world. The fully revised and updated 2018 edition codifies the U.S. government's most current health guidelines and information for international travelers, including pretravel vaccine recommendations, destination-specific health advice, and easy-to-reference maps, tables, and charts. The 2018 Yellow Book also addresses the needs of specific types of travelers, with dedicated sections on: · Precautions for pregnant travelers, immunocompromised travelers, and travelers with disabilities · Special considerations for newly arrived adoptees, immigrants, and refugees · Practical tips for last-minute or resource-limited travelers · Advice for air crews, humanitarian workers, missionaries, and others who provide care and support overseas Authored by a team of the world's most esteemed travel medicine experts, the Yellow Book is an essential resource for travelers -- and the clinicians overseeing their care -- at home and abroad.